|

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

RECRUITINGSponsored by University Medical Center Goettingen
Actively Recruiting
SponsorUniversity Medical Center Goettingen
Started2024-06-20
Est. completion2026-06-01
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06526065

Summary

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Histological diagnosis of DLBCL\&LBCL
2. Planned treatment with guideline-based first-line therapy
3. Patient's consent
4. All genders, Patient age ≥ 18 years
5. Ability to consent

Exclusion Criteria:

1. Treatment with R-CHOP/-like regimens already started
2. Relationship of dependence/ direct employment with the investigator
3. Active HIV-infection
4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)

Conditions2

CancerDLBCL - Diffuse Large B Cell Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.